Pierre Massion
Faculty Member
Last active: 1/11/2018

Poor survival for veterans with pathologic stage I non-small-cell lung cancer.

St Julien JB, Pinkerman R, Aldrich MC, Chen H, Deppen SA, Callaway-Lane C, Massion P, Putnam JB, Lambright ES, Nesbitt JC, Grogan EL
Am J Surg. 2012 204 (5): 637-42

PMID: 22906246 · PMCID: PMC3766956 · DOI:10.1016/j.amjsurg.2012.07.008

BACKGROUND - Pathologic stage (pStage) IA and IB non-small-cell lung cancer (NSCLC) has a median survival time of 119 and 81 months, respectively. We describe the outcomes of veterans with pStage I NSCLC.

METHODS - A retrospective review of 78 patients with pStage I NSCLC who underwent cancer resection was performed at the Tennessee Valley Veterans Affairs Hospital between 2005 and 2010. All-cause 30-day, 90-day, and overall mortality were determined. Survival was assessed with the Kaplan-Meier and Cox proportional hazards methods.

RESULTS - There were 55 (71%) pStage IA and 23 (29%) IB patients. Thirty- and 90-day mortality was 3.8% (3 of 78) and 6.4% (5 of 78), respectively. Median survival was 59 and 28 months for pStage 1A and 1B, respectively. Postoperative events were associated with impaired survival on multivariable analysis (hazard ratio, 1.26, P = .03).

CONCLUSIONS - Veterans with pStage I NSCLC at our institution have poorer survival than the general population. More research is needed to determine the etiology of this disparity.

Published by Elsevier Inc.

MeSH Terms (16)

Aged Carcinoma, Non-Small-Cell Lung Health Status Disparities Humans Lung Neoplasms Male Middle Aged Multivariate Analysis Neoplasm Staging Pneumonectomy Postoperative Complications Retrospective Studies Survival Analysis Tennessee Treatment Outcome Veterans Health

Connections (6)

This publication is referenced by other Labnodes entities: